Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 22Trastuzumab 16Paclitaxel 15Radiotherapy 13Docetaxel 13Capecitabine 11Doxorubicin 10Taxes 9Lapatinib 9Carboplatin 8Tamoxifen 7Immunohistochemistry 7Biopsy 7Albumin-Bound Paclitaxel 7Magnetic Resonance Spectroscopy 6Fluorodeoxyglucose F18 6Chemotherapy, Adjuvant 6Immunoenzyme Techniques 5Gemcitabine 5Flow Cytometry 5Bevacizumab 5sargramostim 4Vinorelbine 4Letrozole 4Irinotecan 4Granulocyte-Macrophage Colony-Stimulating Factor 4Filgrastim 4Everolimus 4Erlotinib Hydrochloride 4Cisplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms, Male × Indomethacin × Clear all
NCT02950259 2025-12-03

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Providence Health & Services

Phase 1 Completed
16 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡